Medullary Breast Carcinoma

Medullary breast carcinoma (MBC) is a rare, yet clinically distinct subtype of breast cancer, accounting for approximately 1-7% of all invasive breast cancer cases. At Alfa Cytology, our team of experienced biologists work with you to develop MBC therapeutics.

Introduction to Medullary Breast Carcinoma

Traditionally, MBC has been considered an aggressive form of breast cancer, owing to its high nuclear grade and triple-negative receptor status (lacking expression of estrogen receptor, progesterone receptor, and HER2). However, the clinical course of MBC often defies this expectation. Contrary to the poor prognosis typically associated with triple-negative breast cancer, MBC has been shown to have a favorable overall survival, with 5-year survival rates ranging from 70-90%.

Fig.1 Main histopathology, markers, and signalling pathways of medullary breast carcinoma. (Mahmoud R., et al. 2022)

Therapy Development for Medullary Breast Carcinoma

Traditionally, the management of MBC has relied on standard treatment modalities used for other breast cancer subtypes, such as surgery, radiation therapy, and systemic chemotherapy. However, the unique biological characteristics of MBC have led to the exploration of more targeted and personalized therapeutic strategies.

Our Services

Medullary breast carcinoma is a relatively rare disease but malignant. Multiple factors influence prognosis and therapy options. Therefore, Alfa Cytology is working on providing one-stop solutions for medullary breast carcinoma, including but not limited to the following. 

Modeling Services for MBC

If your research requires specialized MBC models, our team can work with you to build novel in vitro and in vivo systems to support our clients' drug discovery and translational research efforts.

Alfa Cytology is committed to the research and study of MBC, from molecular biology services, and cancer biomarker discovery services, to preclinical research services, providing one-stop services. Our cancer experts have many years of experience in the development of the latest therapies for MBC. If you are interested in our service, please contact us.